Greg (Jie) Gao

Greg (Jie) Gao has worked in the medical field since 2004. Greg (Jie) began their career as a Project Agent at Shanghai Zhangjiang Biotech Co., Ltd. in 2004. In 2009, they moved to Sanofi as a Clinical Research Monitor and Clinical Safety Officer, where they were involved in international multi-center Phase III clinical trials. In 2011, they joined Covance as a Senior Clinical Research Leader in Oncology Target therapy LUX-Lung 8. In 2013, they moved to Merck as a Clinical Research Physician in Oncology I-O therapy and an Outcomes Researcher in oncology, respiratory disease, and hepatitis B C. In 2018, they joined BeiGene as an Associate Medical Director in Oncology I-O. In 2021, they moved to Novotech Health Holdings as a Medical Director in Oncology. Most recently, they joined Duality Biologics as an Executive Medical Director in 2022.

Greg (Jie) Gao obtained a Master of Public Health (M.P.H.) in Epidemiology from the University of Wollongong between 2007 and 2008. Prior to that, they completed a Bachelor in Clinical Medicine from Shanghai Jiaotong University, School of Medicine between 1999 and 2004.